Research and Innovation Jeremy Bray Policy Advisor Health Directorate DirectorateGeneral for Research and Innovation European Commission Alliance for Biomedical Research in Europe 16 November ID: 641897
Download Presentation The PPT/PDF document "Promoting health research and innovation..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Promoting health research and innovation in Horizon 2020
Research and
Innovation
Jeremy Bray
Policy Advisor
Health Directorate
Directorate-General
for
Research
and Innovation
European Commission
Alliance for Biomedical Research in Europe
16 November
2012Slide2
Summary messages Horizon 2020
We know the health 'what' We know some of the 'how' We don't know the 'how much'…
What about governance?Slide3
If it isn't broken?
Aggregated data 2002-10
1,210
projects funded4.9billion euros invested14,000teams114countries~50%of projects on-going
70,000
PubMed publications
50,000high-skilled jobs 23.3%listed on patent application(s)
17%envisage creating a SME7.4%created one or more SMEsSlide4
The necessity to invest in R&DSlide5
EU v US – fragmentation and underinvestment
Towards joint programming in research Working together to tackle common challenges more effectively, EU COM (2008) 468
Dementia
AlzheimerBrain diseaseCancer
Low coordination/ high fragmentation, invest less than the US
Medium
coordination/
fragmentation, invest less than the USSlide6
H2020 - €80bn for…Excellent science
ERC, FET, Marie Curie, infrastructuresIndustrial leadershipLEIT, risk finance, SMESocietal challengesHealth, Food, Energy, Transport, Climate, SecuritySlide7
In the pipeline:IMI2EDCTP2
SME / SBIRInternational consortiaClinical researchRoll-outCommon characteristics?Slide8
10 regulators
17 patient org
603 million EUR
IMI
JU
cash
contribution
600 million EUR
EFPIA
i
n kindcontribution
~ 3500 researchers
> 200 publications
EU-AIMS
contribution
to
autism
eTOX
contribution to
cardiotoxicity
IMI Key
Figures of
the 37 Projects to dateSlide9
Strategic Business Plan to ensure critical level of commitment to EDCTP2Plans to keep scope and mandateProposal for EU legislation on EDCTP2 co-funding under developmentHigh-Level Conference in Cape Town, 5 Nov 2012
Current
PartnershipRenewal of the "European and Developing Countries Clinical Trials Partnership"Slide10
International Rare Diseases Research Consortium (IRDiRC
)200 new therapies and means to diagnose most rare diseases by the year 2020
© Yuri Arcurs/Fotolia.com
© nyul/Fotolia.comSlide11
Europe
European
Commission
(EU)EURORDIS (EU)French Association against Myopathies (FR)French National Research Agency (FR)German Federal Ministry of Education and research (DE)Italian Higher Institute of Health Research (IT)Italian Telethon Foundation (IT)Lysogene (FR)Netherlands Organisation for Health Research and DevelopmentProsensa (NL)Shire (IE)Spanish Carlos III Health Institute
(ES)UK National Institute for Health Research (UK)
28
committed members
North America
Canadian Institutes for Health Research
(
CA)FDA Orphan Products Grants Program (US)
Genome
Canada
(
CA
)
Genetic Alliance
(US)
Mendelian
Disorders Genome
Centres
(
US)
National Centre for Translational Therapeutics
(US)
National Cancer Institute
(US)
National Institute of Neurological Disorders and Stroke
(US)
National Institute of Arthritis and Musculoskeletal and Skin Diseases
(US)
National Institute of Child Health and Human Development
(US)
National Eye Institute
(US
)
NORD
(US)
Office of Rare Diseases
(US
)
Sanford Research
(US
)
© rtguest/Fotolia.com
Australia
Western Australian Department of HealthSlide12
International
Mouse
ConsortiumInternational Cancer Genomics ConsortiumIRDiRC
: one of several international collaborationsInternational Human Metagenome ConsortiumInternational Human Epigenome ConsortiumInternational Rare Diseases Research ConsortiumInternational Initiative for Traumatic Brain Injury Research
© rtguest/Fotolia.comSlide13
ConclusionsOne size does not fit all
Broader participation brings benefit – is dependent on trust and instrument suited to challengeThis takes time
Governance must also be reflective of this varietySlide14Slide15
a long term endeavour…Slide16
Horizon 2020 timelineFrom 30/11 Parliament and Council negotiations on the basis of the Commission proposals
On-going Parliament and Council negotiations on EU budget 2014-20 (including Horizon 2020)By end 2013 Adoption of legislative acts by Parliament and Council on Horizon 2020
January 2014 Horizon 2020 starts; launch of first calls
2011201220132014